CDC Website CDC Website

To Join the NPIN community or

Home » Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed)

Due to the evolving COVID-19 situation, NPIN may not have the most up-to-date organization changes to services or hours. Please call the organization or visit their website to find out about any changes. This site does not have information about where to get tested for COVID-19. For COVID-19 information please visit: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html

Debido a la rápida evolución de la situación con respecto al COVID-19, NPIN podría no tener la información mas actualizada de los servicios u horas de las organizaciones. Por favor llame o visite la página web de la organización para conocer los cambios. Este sitio no tiene información sobre donde hacerse la prueba del COVID-19. Para información sobre el COVID-19 por favor visite: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html

Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to address the problem of HIV persistence in people living with HIV treated with suppressive antiretroviral drug regimens. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. While some aspect of clinical research is required, unlike the previous iteration of this RFA, clinical trials will no longer be supported. The application must include at least one private sector entity to facilitate rapid translation of basic discovery research into therapeutic development and testing. Collaboratory research should be milestone-based and should be focused on specific innovative approaches to characterize and quantify persistent HIV-1 reservoirs and/or understand and predict post-treatment control of viral rebound, identify and test therapeutic strategies to control viral rebound after discontinuation of antiretroviral therapy, and identify and test strategies to eradicate or permanently inactivate rebound-competent HIV.

Letter of Intent Date
11/7/20
Application Due Date
12/7/20
Project Start Date
7/1/21
Application Contact
Anthony
Agresti
Financial/Grants Management Contact
301-827-8014
agrestia@nhlbi.nih.gov
Technical Contact
Shimian
Zou
Scientific/Research Contact
shimian.zou@nih.gov
301-827-8301
Fund Duration
The total project period must be 5 years.
Subjects
Audiences

Fund Number: 

346938

Fund ID: 

RFA-AI-20-035

Last modified: 

6/16/20